本帖最后由 老马 于 2012-1-13 21:20 编辑
: L/ O# F2 \8 \: t$ Q+ C. f5 J, w; ]3 M+ I4 s" c7 Z/ ^
爱必妥和阿瓦斯丁的比较
' u. U! }6 k) P; u& O3 y/ t/ ?
3 ? k+ o& g9 ]% X/ ]7 z* lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 e: D# n# S5 m5 \9 w( I
) p4 m6 o3 s% U* G. D
6 l0 A% @/ M9 f- Z$ a* A! X
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, F, s/ T$ j [( D( E( C==================================================, a4 F7 W+ l: ?9 [" c& y# F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% i, ~% j0 `: n3 |* ~& _$ vPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 R/ u, v; r9 NResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( Z5 u- j& ~: ~) }4 @! {' u
|